Keywords: PK، فارماکوکینتیک; Artemether; Dihydryartemisinin; Epimerization; Degradation by malaria related hemolytic products; LC–MS/MS; ValidationART, artemether; DHA, dihydroartimisinin; PK, pharmacokinetics; UV, ultraviolet; LLOQ, lower limit of quantitation; APCI, atmospheric pre
مقالات ISI PK، فارماکوکینتیک (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: PK، فارماکوکینتیک; CYP, cytochrome P450; DDI, drug–drug interactions; DPM, disintegrations per minute; HCV, hepatitis C virus; HLM, human liver microsomes; PBPK, Physiologically-based pharmacokinetics; PK, pharmacokinetics; TDI, time-dependent inhibitorCL, clearance; Drug–d
Keywords: PK، فارماکوکینتیک; Hemophilia B; PROLONG-9FP; rIX-FP; Recombinant factor IX; On-demand; ProphylaxisAEs, adverse events; AsBR, annualized spontaneous bleeding rate; FIX, factor IX; IV, intravenous; pdFIX, plasma-derived factor IX; PK, pharmacokinetics; rFIX, recombinant fact
Pharmacokinetics and pharmacodynamics of glycyrrhetinic acid with Paeoniflorin after transdermal administration in dysmenorrhea model mice
Keywords: PK، فارماکوکینتیک; Glycyrrhetinic acid; Paeoniflorin; Pharmacokinetics; Pharmacodynamics; Analgesic; Transdermal drug deliveryPLD, Chinese peony-Liquorice Decoction; GA, glycyrrhetinic acid; PF, paeoniflorin; TTS, transdermal therapeutic system; PK, pharmacokinetics; PD, ph
Quantification of 5,7-dimethoxyflavone in mouse plasma using liquid chromatography–tandem mass spectrometry (LC–MS/MS) and its application to a pharmacokinetic study
Keywords: PK، فارماکوکینتیک; 5,7-DMF, 5,7-dimethoxyflavone; LC–MS/MS, liquid chromatography–tandem mass spectrometry; PK, pharmacokinetics; LLOQ, lower limit of quantification; HPLC, high performance liquid chromatography; GC, gas chromatography; TMF, 5,7,4′-trimethoxyflavone; ACN, a
Garcinol: Current status of its anti-oxidative, anti-inflammatory and anti-cancer effects
Keywords: PK، فارماکوکینتیک; Garcinia indica; Garcinol; Pharmacodynamics; Pharmacokinetics; ToxicologyG. indica, Garcinia indica; PD, pharmacodynamics; PK, pharmacokinetics; ADME, absorption, distribution, metabolism and elimination; OH•−, hydroxyl radical; ROS, reactive oxygen speci
Impact of IgG2 high molecular weight species on neonatal Fc receptor binding assays
Keywords: PK، فارماکوکینتیک; HMWs; Aggregates; SEC; Antibody; FcRn bindingmAb, monoclonal antibody; FcRn, neonatal Fc receptor; PK, pharmacokinetics; AlphaScreen, amplified luminescent proximity homogeneous assay screen; SEC, size exclusion chromatography; HMWs, high molecular weight
Are children undergoing cardiac surgery receiving antibiotics at subtherapeutic levels?
Keywords: PK، فارماکوکینتیک; 16; 20; 27; 41.1%fT, percent of dosing interval; Cmax, maximum total plasma concentration; CPB, cardiopulmonary bypass; IV, intravenous; MIC, minimal inhibitory concentration; PK, pharmacokinetics; VD, volume of distribution
Metabolism and physiologically based pharmacokinetic modeling of flumioxazin in pregnant animals
Keywords: PK، فارماکوکینتیک; PBPK, physiologically based pharmacokinetics; Km, Michaelis–Menten constant; Vmax, maximum velocity; PPO, protoporphyrinogen oxidase; NMR, nuclear magnetic resonance; MS, mass spectrometry; PK, pharmacokinetics; LSC, liquid scintillation counter; Pt, part
The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) Trial for Femoropopliteal Revascularization : First-in-Human Randomized Trial of Low-Dose Drug-Coated Balloon Versus Uncoated Balloon Angioplasty
Keywords: PK، فارماکوکینتیک; angioplasty; drug-coated balloon; drug-eluting balloon; paclitaxel; peripheral vascular disease; restenosisDCB, drug-coated balloon(s); ITT, intention to treat; LLL, late lumen loss; PK, pharmacokinetics; TLR, target lesion revascularization(s)
Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors
Keywords: PK، فارماکوکینتیک; FAAH, fatty acid amide hydrolase; EC, endogenous cannabinoid; AEA, arachidonoylethanolamide; CB1, cannabinoid 1; CB2, cannabinoid 2; SAR, Structure–activity relationship; DMPK, drug metabolism and pharmacokinetics; PK, pharmacokinetics; PD, pharmacodynami
Lead optimization of isocytosine-derived xanthine oxidase inhibitors
Keywords: PK، فارماکوکینتیک; XOR, xanthine oxidoreductase; XO, xanthine oxidase; PK, pharmacokinetics; AUC, area under curve; XDH, xanthine dehydrogenase; ip, intraperitoneal; po, per oral; SAR, structure–activity relationship; UA, uric acid; sUA, serum UAXanthine oxidase inhibitors;
A mass balance approach for calculation of recovery and binding enables the use of ultrafiltration as a rapid method for measurement of plasma protein binding for even highly lipophilic compounds
Keywords: PK، فارماکوکینتیک; ADME, absorption, distribution, metabolism, excretion; ED, equilibrium dialysis; EP, eppendorf; NSB, non-specific binding; PD, pharmacodynamics; PK, pharmacokinetics; PPB, plasma protein binding; RED, rapid equilibrium dialysis; UF, ultrafiltrationPlasma
The role of hepatic transport and metabolism in the interactions between pravastatin or repaglinide and two rOatp inhibitors in rats
Keywords: PK، فارماکوکینتیک; Oatp, organic anion transporting polypeptide; PK, pharmacokinetics; Oct1, organic cation transporter 1; HBSS, Hank’s balanced salt solution; LC-MS, liquid chromatography tandem mass spectrometry; HP-β cyclodextrin, 2-hydroxypropyl-beta-cyclodextrin; EDTA,
Pegvisomant bioavailability of single 30 mg/mL subcutaneous injection compared to two 15 mg/mL subcutaneous injections: A pharmacokinetic, safety and tolerability study
Keywords: PK، فارماکوکینتیک; SC, subcutaneous or subcutaneously; IV, intravenous or intravenously; PK, pharmacokinetics; BA, bioavailability; relBA, relative bioavailabilityPegvisomant; Pharmacokinetics; Relative bioavailability; Subcutaneous injection; Acromegaly
Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody
Keywords: PK، فارماکوکینتیک; IgG, immunoglobulin G; FcγR, Fc receptors for IgG; ITP, immune thrombocytopenic purpura; mAbs, monoclonal antibodies; PK, pharmacokinetics; PD, pharmacodynamics; AUC, area under the concentration vs. time profiles; CL, clearance; Vss, volume of distributi
Bisoprolol, ramipril and simvastatin determination in dried blood spot samples using LC–HRMS for assessing medication adherence
Keywords: PK، فارماکوکینتیک; PK, pharmacokinetics; DBS, dried blood spot; LC–HRMS, liquid chromatography–high resolution mass spectrometryDried blood spot (DBS); LC–HRMS; Cardiovascular drugs; Adherence
A biomathematical model of the restoring effects of caffeine on cognitive performance during sleep deprivation
Keywords: PK، فارماکوکینتیک; PD, Pharmacodynamic; PK, Pharmacokinetics; PVT, Psychomotor Vigilance Test; RMSE, Root Mean Squared ErrorCaffeine model; Sleep loss; PVT; Individualized modeling; Pharmacokinetic–pharmacodynamic model
Dynamical models of biomarkers and clinical progression for personalized medicine: The HIV context
Keywords: PK، فارماکوکینتیک; HIV, Human Immunodeficiency Virus; HAART, Highly Active antiretroviral Therapy; TDM, Therapeutic Drug monitoring; STI, Structured Treatment Interruptions; ODE, Ordinary Differential Equation; PK, Pharmacokinetics; PD, Pharmacodynamics; PG, Pharmacogenomic
Sciatic nerve regeneration is not inhibited by anti-NGF antibody treatment in the adult rat
Keywords: PK، فارماکوکینتیک; ANOVA, analysis of variance; BLQ, below level of quantitation; DRG, dorsal root ganglion; FG, Fluoro-Gold; NGF, nerve growth factor; PK, pharmacokinetics; SFI, Sciatic Functional Indexnerve growth factor; peripheral nerve regeneration; anti-NGF treatment
A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D3 is revealed using a novel LC–MS/MS assay
Keywords: PK، فارماکوکینتیک; 1,25(OH)2D3, 1,25-dihydroxyvitamin D3; FBS, fetal bovine serum; GUS, β-glucuronidase; LC–MS/MS, liquid chromatography–tandem mass spectrometry; PK, pharmacokinetics; qPCR, quantitative PCRLung cancer; CTA091; CYP24; 1,25-Dihydroxyvitamin D3; Pharmacokinet
Investigation of dried blood spot card-induced interferences in liquid chromatography/mass spectrometry
Keywords: PK، فارماکوکینتیک; DBS, dried blood spotting; PK, pharmacokinetics; RT, retention time; WB, whole blood; SDS, sodium dodecyl sulfate; IS, internal standard; DMSO, dimethyl sulfoxideLiquid chromatography/mass spectrometry; Dried blood spotting; Interference; Ion-pairing; FTA
Validation of a gyrolab™ assay for quantification of rituximab in human serum
Keywords: PK، فارماکوکینتیک; PK, pharmacokinetics; ELISA, enzyme-linked immunosorbent assay; CD, compact disk; PBS, phosphate buffered saline; HABA, 4′-hydroxyazobenzene-2-carboxylic acid; QC, quality control; LLOQ, lower limit of quantification; ULOQ, upper limit of quantification;
Quantitative determination of atenolol in dried blood spot samples by LC–HRMS: A potential method for assessing medication adherence
Keywords: PK، فارماکوکینتیک; PK, pharmacokinetics; DBS, dried blood spot; LC–HRMS, liquid chromatography–high resolution mass spectrometryDried blood spot (DBS); Atenolol; Accurate mass; Guthrie card; LC–HRMS; Adherence
Orally bioavailable allosteric CCR8 antagonists inhibit dendritic cell, T cell and eosinophil migration
Keywords: PK، فارماکوکینتیک; DC, dendritic cell; LPS, lipopolysaccharide; PK, pharmacokinetics; GPCR, G-protein-coupled receptor; hERG, human ether-à-go-go related gene; FEV1, forced expiratory volume 1; KO, knock-out; wt, wild-type; CYP, cytochrome P450; MEC, minimal effective conce
Lung imaging — Two dimensional gamma scintigraphy, SPECT, CT and PET
Keywords: PK، فارماکوکینتیک; SPECT, single photon emission computed tomography; CT, computed tomography; HRCT, high resolution computed tomography; PET, positron emission tomography; PK, pharmacokinetics; MMAD, mass median aerodynamic diameter; GSD, geometric standard deviation; MDI,
Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: A comparative study with CHO produced materials
Keywords: PK، فارماکوکینتیک; Glycoengineering; Pichia pastoris; Pharmacokinetics; Monoclonal antibody; Mannose; AfucosylationmAb, monoclonal antibody; Fc, antibody fragment crystallizable; FcRn, Neonatal Fc receptor; FcγR, Fc gamma receptor; PK, Pharmacokinetics; PD, Pharmacodynamics
Evaluation of pharmacokinetic and pharmacodynamic relationship for oral sustained-release atenolol pellets in rats
Keywords: PK، فارماکوکینتیک; AT, atenolol; SRPs, sustained-release pellets; IRPs, immediate-release pellets; PK, pharmacokinetics; PD, pharmacodynamics; HRs, hypertensive rats; SBP, systolic pressureAtenolol; Pharmacokinetics; Pharmacodynamics; Sustained-release pellets; PK–PD relati
Targeting angiogenesis with compounds from the extracellular matrix
Keywords: PK، فارماکوکینتیک; AAV, adeno-associated virus; ECM, extracellular matrix; FGF, fibroblast growth factor; HSPG, heparan sulfate proteoglycans; MMP, matrix metalloproteinases; NC1, non-collagenous domain 1; PD, pharmacodynamics; PK, pharmacokinetics; TIMP, tissue inhibitor o
Absorption and tissue distribution of a novel carboxymethyldextran after oral administration
Keywords: PK، فارماکوکینتیک; i.p., Intraperitoneal injection; i.v., Intravenous injection; F, Bioavailability; AUMC, Area under the first moment curve; RGTA, for ReGeneraTing Agent; PK, Pharmacokinetics; Vd, Volume of distribution; AUCCL, Area under curve; CL, Clearance; Cmax, Maximu
Dexamethasone quantification in dried blood spot samples using LC–MS: The potential for application to neonatal pharmacokinetic studies
Keywords: PK، فارماکوکینتیک; CLD, chronic lung disease; PK, pharmacokinetics; DBS, dried blood spotDried blood spot (DBS); Dexamethasone; Chronic lung disease; Guthrie card; LC–MS
Drug interactions evaluation: An integrated part of risk assessment of therapeutics
Keywords: PK، فارماکوکینتیک; NDA, new drug application; NME, new molecular entity; ADME, absorption, distribution, metabolism, and/or excretion; PK, pharmacokinetics; PD, pharmacodyanmics; CYP, cytochrome P450; UGT, uridine diphosphate (UDP)-glucuronosyl transferase; P-gp, P-glycopro
Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model
Keywords: PK، فارماکوکینتیک; CYP2D6, Cytochrome P450 2D6; PK, pharmacokinetics; PD, pharmacodynamics; EM, extensive metabolizer; PM, poor metabolizer; Tg-CYP2D6, CYP2D6-humanized; IDR, indirect response; HPLC, high performance liquid chromatography; LC-MS/MS, liquid chromatography ta
Non-linear pharmacodynamics in the transfection efficiency of a non-viral gene delivery system
Keywords: PK، فارماکوکینتیک; pDNA, plasmid DNA; PK, pharmacokinetics; PD, pharmacodynamics; NCL, normal concentration lipoplex; LCL, low concentration lipoplex; CIDIQ, confocal image-assisted three-dimensionally integrated quantification; LFN, LipofectAMINE PLUS; R8-MEND, octaarginin
Isolation of human anti-idiotypic antibodies by phage display for clinical immune response assays
Keywords: PK، فارماکوکینتیک; pK, pharmacokinetics; IR, immune response; Ab, antibody; mAb, monoclonal antibody; ADA, anti-drug antibody; IgG, immunoglobulin; λ, lambda light chain of an antibody; κ, kappa light chain of an antibody; VH, variable region of the heavy chain of an antibo
Vascular disrupting agents
Keywords: PK، فارماکوکینتیک; VTA, vascular targeting agent; VDA, vascular disrupting agent; TNF-α, tumor necrosis factor α; IFN, interferon; MTD, maximum tolerated dose; PK, pharmacokinetics; PD, pharmacodynamics; TBA, tubulin-binding agent; RhoA, ras homolog gene family (member A);